FDA accelerates review of Exelixis' thyroid cancer drug cabozantinib
03:38 EDT 31 Jul 2012 | SmartBrief
Exelixis obtained priority-review status from the FDA for cabozantinib, an experimental drug for progressive, unresectable, l -More-
Original Article: FDA accelerates review of Exelixis' thyroid cancer drug cabozantinib
More From BioPortfolio on "FDA accelerates review of Exelixis' thyroid cancer drug cabozantinib"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
